SEC Form 4 · accession 0000899243-18-000074
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tyler Dylan-Hyde
Officer — Chief Legal Officer
Period of report
Dec 28, 2017
Accepted (ET)
Jan 2, 2018 · 4:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Dec 28, 2017 | M | 700 | $14.43 | A | 115,904 | D | |
| Common Shares | Dec 28, 2017 | S | 700 | $21.75 | D | 115,204 | D | |
| Common Shares | Dec 29, 2017 | M | 6,230 | $14.43 | A | 121,434 | D | |
| Common Shares | Dec 29, 2017 | S | 6,230 | $21.75 | D | 115,204 | D | |
| Common Shares | Dec 29, 2017 | M | 9,070 | $12.57 | A | 124,274 | D | |
| Common Shares | Dec 29, 2017 | S | 1,070 | $21.75 | D | 123,204 | D | |
| Common SharesF2 | Dec 29, 2017 | S | 8,000 | $23.76 | D | 115,204 | D | |
| Common SharesF3 | Dec 29, 2017 | S | 15,000 | $22.68 | D | 100,204 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $14.43 | Dec 28, 2017 | M | 700 | D | — | Jun 15, 2027 | Common Shares | 700 | 64,300 | D |
| Stock Option (Right to Buy)F4 | $14.43 | Dec 29, 2017 | M | 6,230 | D | — | Jun 15, 2027 | Common Shares | 6,230 | 58,070 | D |
| Stock Option (Right to Buy)F5 | $12.57 | Dec 29, 2017 | M | 9,070 | D | — | Jul 15, 2026 | Common Shares | 9,070 | 44,263 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.7606 to $23.90, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.6771 to $23.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F4This option was granted on June 15, 2017 with respect to 65,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017.
- F5This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.